<div id="readability-page-1"><p>01:35 PM EST, 12/29/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:</p><p>We reduce our target price to $422 from $470 based on our NPV analysis. We maintain our 2025 EPS forecast at $4.98 and our 2026 view at $9.72. We updated our model and slightly lowered our full-year 2025 revenue estimate to $3.8B from $3.9B, as we now see the TTR franchise revenue closer to $2.49B, at the lower end of the revenue guidance range of $2.475B-$2.525B shared in October. At the same time, we see the recently announced manufacturing investment as a positive decision for the long term, as it aims to increase capacity and reduce costs. In early December, ALNY announced a significant manufacturing investment worth $250M to expand its Norton, MA facility, which is expected to position ALNY as an innovation hub. By expanding its existing site, which is planned to be completed in late 2027, ALNY aims to produce both clinical and commercial supply of siRNA oligonucleotide drug substance globally. Shares of ALNY went down by more than 17% since we lowered our rating to Hold from Buy on October 29.</p> <p>MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</p></div>

阿里拉姆制药

<p>CFRA 对阿里拉姆制药保持持有评级，并根据净现值分析将目标价格从 470 美元下调至 422 美元。2025 年每股收益预测仍为 4.98 美元，2025 年全年收入预估略微下调至 38 亿美元。TTR 产品线的收入现预计为 24.9 亿美元。最近的一项 2.5 亿美元的制造投资旨在提升产能并降低成本，使阿里拉姆成为创新中心。自 10 月 29 日评级调整为持有以来，股价已下跌超过 17%</p>

研究警报：CFRA 维持对 Alnylam Pharmaceuticals, Inc.股票的持有意见